Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
128 participants
OBSERVATIONAL
2013-04-30
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of Autoreactive Regulatory and Conventional CD4 T Cells in Recent Onset Type 1 Diabetes and Control Individuals
NCT06427421
Imaging of Type 1 Diabetes Progression
NCT01521520
The Influence of Partial Remission Phase of Type 1 Diabetes on Patient Outcome
NCT02220257
Immune Function and the Progression to T1D
NCT05899439
The Role of Regulatory T Cell in Patients With Type 1 Diabetes Mellitus
NCT00173641
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1a
Patients with type 1 diabetes who have undetectable c-peptide ( ≤0.1 ng/mL) levels after mixed meal tolarance test: group 1a
No interventions assigned to this group
Group 1b
Patients with type 1 diabetes who have c-peptide levels between 0.1-0.8 ng/mL after mixed meal tolerance test: group 1b
No interventions assigned to this group
Group 1c
Patients with type 1 diabetes who have c-peptide levels ≥0.8ng/mL after mixed meal tolerance test: group 1c
No interventions assigned to this group
Control
Healthy subjects
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with type 1 diabetes according to WHO definiton
Exclusion Criteria
* significant concomitant diseases which may interfere with glucose metabolism
* cancers,
* hemoglobinopathies,
* recently received antibiotics,
* drugs influencing β-cell function and
* insulin sensitivity or anti-inflammatory drugs
* recent history of trauma
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Medeniyet University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gonca Incemehmet Tamer
Assoc prof
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medeniyet University Goztepe Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Interleukins in type 1diabetes
Identifier Type: REGISTRY
Identifier Source: secondary_id
MUGEAH-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.